108787-56-0Relevant articles and documents
Synthesis and Biological Evaluations of a Series of Thaxtomin Analogues
Zhang, Hongbo,Wang, Qingpeng,Ning, Xin,Hang, Hang,Ma, Jing,Yang, Xiande,Lu, Xiaolin,Zhang, Jiabao,Li, Yonghong,Niu, Congwei,Song, Haoran,Wang, Xin,Wang, Peng George
, p. 3734 - 3741 (2015)
Thaxtomins are a unique family of phytotoxins with unique 4-nitroindole and diketopiperazine fragments possessing potential herbicidal activities. This work presents the total synthesis of natural product thaxtomin C and its analogues. The extensive struc
Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers
Mitra, Prithiba,Eckenrode, Joseph M.,Mandal, Abhisek,Jha, Amit K.,Salem, Shaimaa M.,Leggas, Markos,Rohr, Jürgen
, p. 8001 - 8016 (2018)
Mithramycin A (1) was identified as the top potential inhibitor of the aberrant ETS transcription factor EWS-FLI1, which causes Ewing sarcoma. Unfortunately, 1 has a narrow therapeutic window, compelling us to seek less toxic and more selective analogues. Here, we used MTMSA (2) to generate analogues via peptide coupling and fragment-based drug development strategies. Cytotoxicity assays in ETS and non-ETS dependent cell lines identified two dipeptide analogues, 60 and 61, with 19.1- and 15.6-fold selectivity, respectively, compared to 1.5-fold for 1. Importantly, the cytotoxicity of 60 and 61 is 100 nM in ETS cells. Molecular assays demonstrated the inhibitory capacity of these analogues against EWS-FLI1 mediated transcription in Ewing sarcoma. Structural analysis shows that positioning the tryptophan residue in a distal position improves selectivity, presumably via interaction with the ETS transcription factor. Thus, these analogues may present new ways to target transcription factors for clinical use.
(Nitro) hymenamide A, unusual biologically active cyclic peptide
Belagali,Himaja,Kumar,Thomas,Prakasini,Poojary
, p. 160 - 164 (2007/10/03)
A new biological active cyclic peptide (Nitro) Hymenamide A has been synthesized and the structure was established on the basis of analytical, IR, NMR and mass spectral data. The new compound was subjected to both antimicrobial and pharmacological studies.